In yesterday’s Wall Street session, Bionomics Ltd. ADR (NASDAQ:BNOX) shares traded at $2.70, down -19.88% from the previous session.
BNOX stock price is now 65.98% away from the 50-day moving average and -5.42% away from the 200-day moving average. The market capitalization of the company currently stands at $22.03M.
With the price target maintained at $8, H.C. Wainwright recently Upgraded its rating from Neutral to Buy for Bionomics Ltd. ADR (NASDAQ: BNOX).
There have been several recent changes in the stakes of large investors in BNOX stock. In total, there are 5 active investors with 3.85% ownership of the company’s stock.
On Friday morning Bionomics Ltd. ADR (NASDAQ: BNOX) stock kicked off with the opening price of $3.2000. During the past 12 months, Bionomics Ltd. ADR has had a low of $0.93 and a high of $10.90. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 9.05, and a quick ratio of 9.05. The fifty day moving average price for BNOX is $1.6281 and a two-hundred day moving average price translates $2.7430 for the stock.
The latest earnings results from Bionomics Ltd. ADR (NASDAQ: BNOX) was released for Jun, 2023. The net profit margin was -9031.53% and return on equity was -44.92% for BNOX. For the current quarter, analysts expect BNOX to generate $260k in revenue.
Bionomics Ltd. ADR(BNOX) Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
